Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD.

Blood Adv · 2021 · PMC8759141 · PMID 34619767

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A similar effect was observed in B6 recipients of BALB/c ILC2 given therapeutically, with >50% of recipients surviving up to 60 days ( Figure 3C-D ), which also did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.